- Home
- PASG vs ELEV Comparison
PASG vs ELEV Comparison
Compare PASG & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASG
- ELEV
- Stock Information
- Founded
- PASG 2017
- ELEV 2019
- Country
- PASG United States
- ELEV United States
- Employees
- PASG N/A
- ELEV N/A
- Industry
- PASG Biotechnology: Pharmaceutical Preparations
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- PASG Health Care
- ELEV Health Care
- Exchange
- PASG Nasdaq
- ELEV Nasdaq
- Market Cap
- PASG 20.3M
- ELEV 22.6M
- IPO Year
- PASG 2020
- ELEV 2021
- Fundamental
- Price
- PASG $7.44
- ELEV $0.37
- Analyst Decision
- PASG Strong Buy
- ELEV Hold
- Analyst Count
- PASG 3
- ELEV 6
- Target Price
- PASG $153.33
- ELEV $1.77
- AVG Volume (30 Days)
- PASG 98.1K
- ELEV 1.2M
- Earning Date
- PASG 08-07-2025
- ELEV 08-05-2025
- Dividend Yield
- PASG N/A
- ELEV N/A
- EPS Growth
- PASG N/A
- ELEV N/A
- EPS
- PASG N/A
- ELEV N/A
- Revenue
- PASG N/A
- ELEV N/A
- Revenue This Year
- PASG N/A
- ELEV N/A
- Revenue Next Year
- PASG N/A
- ELEV N/A
- P/E Ratio
- PASG N/A
- ELEV N/A
- Revenue Growth
- PASG N/A
- ELEV N/A
- 52 Week Low
- PASG $5.12
- ELEV $0.22
- 52 Week High
- PASG $26.60
- ELEV $3.09
- Technical
- Relative Strength Index (RSI)
- PASG 53.78
- ELEV 45.79
- Support Level
- PASG $5.12
- ELEV $0.35
- Resistance Level
- PASG $5.99
- ELEV $0.38
- Average True Range (ATR)
- PASG 0.88
- ELEV 0.01
- MACD
- PASG -0.03
- ELEV -0.00
- Stochastic Oscillator
- PASG 58.25
- ELEV 34.34
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.